Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | PIK3CA | P42336 | 16/20 | 0.43 |
| ▸ | PIK3CD | O00329 | 15/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15074483 | 1.00 | TSHR (0.48) | TSHRSMN1; SMN2MAPK1PIK3CAPIK3CD | |
| SCHEMBL15053338 | 1.00 | TSHR (0.48) | TSHRSMN1; SMN2MAPK1PIK3CAPIK3CD | |
| SCHEMBL22518619 | 0.87 | SMN1; SMN2 (0.46) | TSHRSMN1; SMN2MAPK1PIK3CAPIK3CD | |
| SCHEMBL22518621 | 0.87 | SMN1; SMN2 (0.46) | TSHRSMN1; SMN2MAPK1PIK3CAPIK3CD | |
| SCHEMBL22518582 | 0.87 | SMN1; SMN2 (0.46) | TSHRSMN1; SMN2MAPK1PIK3CAPIK3CD | |
| SCHEMBL7361099 | 0.80 | HPGD (0.47) | TSHRSMN1; SMN2RECQLALDH1A1 | |
| SCHEMBL24174014 | 0.77 | PDE4B (0.35) | PIK3CAPIK3CD | |
| SCHEMBL2679564 | 0.77 | TP53 (0.32) | — | |
| SCHEMBL22686919 | 0.77 | PDE4B (0.35) | PIK3CAPIK3CD | |
| SCHEMBL344785 | 0.77 | TP53 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2794600-B1 | 2,3-Dihydro-benzo[1,4]oxazine derivatives and related compounds as phosphoinositide-3 kinase (PI3K) inhibitors for the treatment of e.g. rheumatoid arthritis | NOVARTIS AG (CH) | 2017-12-06 | — | — | EP | disclosed |
| EP-2794600-B1 | 2,3-Dihydro-benzo[1,4]oxazine derivatives and related compounds as phosphoinositide-3 kinase (PI3K) inhibitors for the treatment of e.g. rheumatoid arthritis | NOVARTIS AG (CH) | 2017-12-06 | — | — | EP | disclosed |
| US-9763952-B2 | Dihydro-benzo-oxazine and dihydro-pyrido-oxazine derivatives | NOVARTIS AG (CH) | 2017-09-19 | — | — | US | disclosed |
| US-9763952-B2 | Dihydro-benzo-oxazine and dihydro-pyrido-oxazine derivatives | NOVARTIS AG (CH) | 2017-09-19 | — | — | US | disclosed |
| US-9763952-B2 | Dihydro-benzo-oxazine and dihydro-pyrido-oxazine derivatives | NOVARTIS AG (CH) | 2017-09-19 | — | — | US | disclosed |
| US-9539260-B2 | Dihydro-benzo-oxazine and dihydro-pyrido-oxazine derivatives | NOVARTIS AG (CH) | 2017-01-10 | — | — | US | disclosed |
| US-9539260-B2 | Dihydro-benzo-oxazine and dihydro-pyrido-oxazine derivatives | NOVARTIS AG (CH) | 2017-01-10 | — | — | US | disclosed |
| US-9539260-B2 | Dihydro-benzo-oxazine and dihydro-pyrido-oxazine derivatives | NOVARTIS AG (CH) | 2017-01-10 | — | — | US | disclosed |
| US-20160106753-A1 | Dihydro-Benzo-Oxazine and Dihydro-Pyrido-Oxazine Derivatives | NOVARTIS AG (CH) | 2016-04-21 | — | — | US | disclosed |
| US-20160106753-A1 | Dihydro-Benzo-Oxazine and Dihydro-Pyrido-Oxazine Derivatives | NOVARTIS AG (CH) | 2016-04-21 | — | — | US | disclosed |
| US-20160106753-A1 | Dihydro-Benzo-Oxazine and Dihydro-Pyrido-Oxazine Derivatives | NOVARTIS AG (CH) | 2016-04-21 | — | — | US | disclosed |
| EP-2794600-A1 | DIHYDRO-BENZO-OXAZINE AND DIHYDRO-PYRIDO-OXAZINE DERIVATIVES | Novartis AG (CH) | 2014-10-29 | — | — | EP | disclosed |
| WO-2013093849-A1 | DIHYDRO-BENZO-OXAZINE AND DIHYDRO-PYRIDO-OXAZINE DERIVATIVES | NOVARTIS AG (CH) | 2013-06-27 | — | — | WO | disclosed |
| WO-2013093849-A1 | DIHYDRO-BENZO-OXAZINE AND DIHYDRO-PYRIDO-OXAZINE DERIVATIVES | NOVARTIS AG (CH) | 2013-06-27 | — | — | WO | disclosed |
| US-20130165436-A1 | Dihydro-Benzo-Oxazine and Dihydro-Pyrido-Oxazine Derivatives | NOVARTIS AG (CH) | 2013-06-27 | — | — | US | disclosed |
| US-20130165436-A1 | Dihydro-Benzo-Oxazine and Dihydro-Pyrido-Oxazine Derivatives | NOVARTIS AG (CH) | 2013-06-27 | — | — | US | disclosed |
| US-20130165436-A1 | Dihydro-Benzo-Oxazine and Dihydro-Pyrido-Oxazine Derivatives | NOVARTIS AG (CH) | 2013-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130165436-A1 | Dihydro-Benzo-Oxazine and Dihydro-Pyrido-Oxazine Derivatives | PDXK, PDK1, DPYD | TSHR 3276/4885SMN1; SMN2 968/4885MAPK1 773/4885 |
| US-20160106753-A1 | Dihydro-Benzo-Oxazine and Dihydro-Pyrido-Oxazine Derivatives | PDXK, PDK1, DPYD | TSHR 3276/4885SMN1; SMN2 968/4885MAPK1 773/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.